KEI Comments on the Medicines Patent Pool/Merck License for Molnupiravir

(For more resources, please see our page on molnupiravir.) The Medicines Patent Pool (MPP) and Merck Sharp & Dohme (“MSD” or “Merck”) have announced a voluntary license for the generic manufacture and sale of molnupiravir. A joint press release from… Continue Reading

KEI Comments Regarding NIH Exclusive License to Progeria Research Foundation for Ultra-Rare Disease Treatment

Knowledge Ecology International (KEI) filed comments on July 27, 2021 regarding the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene” (86 FR 36563). The inventions are currently co-owned… Continue Reading

KEI Comments to NIH Regarding Proposed Exclusive License to PTC Therapeutics for Gene Therapy

On July 27, 2021, Knowledge Ecology International (KEI) commented on the “Prospective Grant of an Exclusive Patent License: RP2 AAV-Based Gene Human Therapy for Ocular Diseases and Disorders Including XLRP” (86 FR 36565). The National Institutes of Health (NIH) intends… Continue Reading

KEI Comments Regarding NIH Proposed Exclusive License to Yeda

(Update: The NIH provided the following response on July 30, 2021.) Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health’s (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: High ASS1 Expressing… Continue Reading

WHA74: KEI’s statement on Public health emergencies: preparedness and response

At the World Health Organization’s 74th World Health Assembly, Knowledge Ecology International delivered the following remarks on “Public health emergencies: preparedness and response” on Monday, 31 May 2021. Non-state actors are limited to one minute statements. Knowledge Ecology International asks… Continue Reading